Skip to main content

Table 4 Trial outcome measures

From: Improving delivery of secondary prophylaxis for rheumatic heart disease in remote Indigenous communities: study protocol for a stepped-wedge randomised trial

Primary outcome

• Proportion of clients receiving 80 % or more of their scheduled benzathine penicillin G (BPG) injections over the 12-month intervention period, compared with the pre-intervention period

Secondary outcomes

• The proportion of scheduled injections that a client receives in a 12-month period

• The average number of days at risk. ‘Days at risk’ is the number of days over 28 days between scheduled injections in a month. For clients on 3-weekly injections, ‘Days at risk’ is the number of days over 21 days between scheduled injections

• Proportion of clients receiving at least 90 % of scheduled BPG injections over a minimum 12-month period

• Proportion of clients receiving 50–79 % and <50 % of scheduled BPG injections over a minimum 12 month period

• Recurrence rate and proportion of ARF episodes that are recurrences, compared to non-participating communities and to the whole jurisdiction

• Impact of the intervention on RHD clients’ experience of care including their perception and understanding of the disease and its management

• Improvement in delivery of other services for RHD clients

• Effect of the programme on delivery of other routine services

  1. ARF acute rheumatic fever, RHD rheumatic heart disease